Developing collaborations and partnerships is a key part of our mission to help transform the lives of people living with cancer. We are committed to alliances, partnerships and collaborations and are continually evaluating new opportunities to expand our pipeline, geographic reach, or technological knowhow.
Our collaborative efforts are focused around our clinical stage programs and other areas including our antibody-drug conjugate platform.
- Clovis Oncology
- Dana Farber Cancer Institute
- Fred Hutchinson Cancer Center
- German Breast Group
- Mass General Cancer Center
- Memorial Sloan Kettering Cancer Center
- University of Wisconsin
- Yale University
- University of Texas Health Science Center at San Antonio
- BSP Pharmaceuticals
- Johnson Matthey (JMPS)
- Millipore Sigma
- Samsung Biologics
Greater China and ASEAN
- Everest Medicines
Sharing our resources with partners allows us to increase the speed and accuracy of the clinical testing process, while opening new doors to discovery and innovation.
We are also involved in indication-specific studies where we collaborate with partners during the development process to determine all the ways our treatments may be effective for a broad range of people in need. We’ve pioneered and validated an antibody-drug conjugate (ADC) technology that targets Trop-2, a protein found on many solid tumors.
If you are interested in partnering with us on the above areas, please contact us.